Encouraging results for tisotumab vedotin combo in cervical cancer released at ESMO

Interim data from two cohorts of the Phase Ib/II innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 as part of a featured mini oral presentation from the drug’s developer, USA-based Seagen (Nasdaq: SGEN) and Danish biotech Genmab (Nasdaq: GMAB).

Initial results from these two dose expansion cohorts of the study showed encouraging and durable anti-tumor activity with tisotumab vedotin in combination with carboplatin (Cohort D) as first-line therapy for patients with advanced cervical cancer who had not received prior systemic therapy, with a 55% objective response rate (ORR) and with tisotumab vedotin in combination with Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab (Cohort F) for patients with advanced cervical cancer who experienced disease progression after 1-2 lines of prior systemic therapy, with a 38% ORR. Both combinations demonstrated a manageable and acceptable safety profile, with no new safety signals identified.

Additionally, median progression free survival (PFS) was 9.5 months in the 1L TV plus carboplatin cohort and 5.6 months in the 2L/3L TV plus pembrolizumab cohort. Safety was consistent with the known safety profiles, and no new safety signals were observed.